Helicobacter pylori

Sleisenger and Fordtran’s Gastrointestinal and Liver Disease- 2 Volume Set: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features and Print

Volumn , Issue , 2010, Pages 833-843

  Peura, David A ^a   Crowe, Sheila E ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649671825     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6189-2.00050-0     Document Type: Chapter

References (177)

1. Amieva MR., El-Omar EM Host-bacterial interactions in Helicobacter pylori infection Gastroenterology 134 2008 306-323(Ref 5.)
2. Blaser MJ., Atherton JC Helicobacter pylori persistence: Biology and disease J Clin Invest 113 2004 321-333(Ref 26.)
3. Chey WD., Wong BC American College of Gastroenterology guideline on the management of Helicobacter pylori infection Am J Gastroenterol 102 2007 1808-1825(Ref 131.)
4. Correa P., Houghton J Carcinogenesis of Helicobacter pylori Gastroenterology 133 2007 659-672(Ref 119.)
5. Ernst PB., Peura DA., Crowe SE The translation of Helicobacter pylori basic research to patient care Gastroenterology 130 2006 188-206(Ref 2.)
6. Gillen D., McColl KE Gastroduodenal disease, Helicobacter pylori, and genetic polymorphisms Clin Gastroenterol Hepatol 3 2005 1180-1186(Ref 6.)
7. Jafri NS., Hornung CA., Howden CW Meta-analysis: Sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment Ann Intern Med 148 2008 923-931(Ref 155.)
8. Jodlowski TZ., Lam S., Ashby CR Emerging therapies for the treatment of Helicobacter pylori infections Ann Pharmacother 42 2008 1621-1639(Ref 151.)
9. Malfertheiner PF., Megraud C., O’Morain F., et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report Gut 56 2007 772-781(Ref 129.)
10. Megraud F., Lehours P Helicobacter pylori detection and antimicrobial susceptibility testing Clin Microbiol Rev 20 2007 280-322(Ref 138.)
11. Naumann M., Crabtree JE Helicobacter pylori-induced epithelial cell signalling in gastric carcinogenesis Trends Microbiol 12 2004 29-36(Ref 46.)
12. Suerbaum S., Michetti P Helicobacter pylori infection N Engl J Med 347 2002 1175-1186(Ref 4.)
13. Talley NJ., Vakil N Guidelines for the management of dyspepsia Am J Gastroenterol 100 2005 2324-2337(Ref 132.)
14. Vakil N., Megraud F Eradication therapy for Helicobacter pylori Gastroenterology 133 2007 985-1001(Ref 148.)
15. Versalovic J Helicobacter pylori. Pathology and diagnostic strategies Am J Clin Pathol 119 2003 403-412(Ref 137.)
16. Kusters JG., van Vliet AH., Kuipers EJ Pathogenesis of Helicobacter pylori infection Clin Microbiol Rev 19 2006 449-490.
17. Ernst PB., Peura DA., Crowe SE The translation of Helicobacter pylori basic research to patient care Gastroenterology 130 2006 188-206.
18. Schubert ML., Peura DA Control of gastric acid secretion in health and disease Gastroenterology 134 2008 1842-1860.
19. Suerbaum S., Michetti P Helicobacter pylori infection N Engl J Med 347 2002 1175-1186.
20. Amieva MR., El-Omar EM Host-bacterial interactions in Helicobacter pylori infection Gastroenterology 134 2008 306-323.
21. Gillen D., McColl KE Gastroduodenal disease, Helicobacter pylori, and genetic polymorphisms Clin Gastroenterol Hepatol 3 2005 1180-1186.
22. Megraud F A humble bacterium sweeps this year’s Nobel Prize Cell 123 2005 975-976.
23. Linz B., Balloux F., Moodley Y., et al. An African origin for the intimate association between humans and Helicobacter pylori Nature 445 2007 915-918.
24. Kivi M., Tindberg Y Helicobacter pylori occurrence and transmission: A family affair? Scand J Infect Dis 38 2006 407-417.
25. Brown LM Helicobacter pylori: Epidemiology and routes of transmission Epidemiol Rev 22 2000 283-297.
26. Rowland M., Daly L., Vaughan M., et al. Age-specific incidence of Helicobacter pylori Gastroenterology 130 2006 65-72.
27. Everhart JE., Kruszon-Moran D., Perez-Perez GI., et al. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States J Infect Dis 181 2000 1359-1363.
28. Tsai CJ., Chang MH Seroepidemiologic study of Helicobacter pylori infection in children in Taipei city Acta Paediatrica Sinica 36 1995 254-256.
29. Asaka M., Kimura T., Kudo M., et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population Gastroenterology 102 1992 760-766.
30. Rupnow MF., Shachter RD., Owens DK., Parsonnet J A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States Emerg Infect Dis 6 2000 228-237.
31. Malaty HM., Graham DY., Isaksson I., et al. Co-twin study of the effect of environment and dietary elements on acquisition of Helicobacter pylori infection Am J Epidemiol 148 1998 793-797.
32. Bellack NR., Koehoorn MW., MacNab YC., Morshed MG A conceptual model of water’s role as a reservoir in Helicobacter pylori transmission: A review of the evidence Epidemiol Infect 134 2006 439-449.
33. Weyermann M., Adler G., Brenner H., Rothenbacher D The mother as source of Helicobacter pylori infection Epidemiology 17 2006 332-334.
34. Parsonnet J., Shmuely H., Haggerty T Fecal and oral shedding of Helicobacter pylori from healthy infected adults [In process citation] JAMA 282 1999 2240-2245.
35. Perry S., de la Luz SM., Yang S., et al. Gastroenteritis and transmission of Helicobacter pylori infection in households Emerg Infect Dis 12 2006 1701-1708.
36. Burgers R., Schneider-Brachert W., Reischl U., et al. Helicobacter pylori in human oral cavity and stomach Eur J Oral Sci 116 2008 297-304.
37. Lin SK., Lambert JR., Schembri MA., et al. The prevalence of Helicobacter pylori in practising dental staff and dental students Aust Dent J 43 1998 35-39.
38. De Schryver AA., Van Hooste WL., Van Winckel MA., Van Sprundel MP Helicobacter pylori infection: A global occupational risk for healthcare workers? Int J Occup Environ Health 10 2004 428-432.
39. Dore MP., Malaty HM., Graham DY., et al. Risk factors associated with Helicobacter pylori infection among children in a defined geographic area Clin Infect Dis 35 2002 240-245.
40. Lee A The Helicobacter pylori genome-New insights into pathogenesis and therapeutics N Engl J Med 338 1998 832-833.
41. Blaser MJ., Atherton JC Helicobacter pylori persistence: Biology and disease J Clin Invest 113 2004 321-333.
42. Graham JE., Peek RM., Krishna U., Cover TL Global analysis of Helicobacter pylori gene expression in human gastric mucosa Gastroenterology 123 2002 1637-1648.
43. Merrell DS., Goodrich ML., Otto G., et al. pH-regulated gene expression of the gastric pathogen Helicobacter pylori Infect Immun 71 2003 3529-3539.
44. Mobley HLT., Hu LT., Foxall PA Helicobacter pylori urease: Properties and role in pathogenesis Scand J Gastroenterol 187 1991 39-46.
45. Kawakubo M., Ito Y., Okimura Y., et al. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection Science 305 2004 1003-1006.
46. Wex T., Treiber G., Nilius M., et al. Helicobacter pylori-mediated gastritis induces local downregulation of secretory leukocyte protease inhibitor in the antrum Infect Immun 72 2004 2383-2385.
47. Boren T., Falk P., Roth KA., et al. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens Science 262 1993 1892-1895.
48. Ilver D., Arnqvist A., Ogren J., et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging Science 279 1998 373-377.
49. Linden S., Nordman H., Hedenbro J., et al. Strain-and blood group-dependent binding of Helicobacter pylori to human gastric MUC5AC glycoforms Gastroenterology 123 2002 1923-1930.
50. Mizushima T., Sugiyama T., Komatsu Y., et al. Clinical relevance of the babA2 genotype of Helicobacter pylori in Japanese clinical isolates J Clin Microbiol 39 2001 2463-2465.
51. Fan XJ., Crowe SE., Behar S., et al. The effect of class II MHC expression on adherence of Helicobacter pylori and induction of apoptosis in gastric epithelial cells: A mechanism for Th1 cell-mediated damage J Exp Med 187 1998 1659-1669.
52. Fan X., Gunasena H., Cheng Z., et al. Helicobacter pylori urease binds to class II MHC on gastric epithelial cells and induces their apoptosis J Immunol 165 2000 1918-1924.
53. Clyne M., Dillon P., Daly S., et al. Helicobacter pylori interacts with the human single-domain trefoil protein TFF1 Proc Natl Acad Sci U S A 101 2004 7409-7414.
54. Lefebvre O., Chenard MP., Masson R., et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein Science 274 1996 259-262.
55. Tebbutt NC., Giraud AS., Inglese M., et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice Nat Med 8 2002 1089-1097.
56. Medzhitov R Toll-like receptors and innate immunity Nat Rev Immunol 1 2001 135-145.
57. Su B., Ceponis PJ., Lebel S., et al. Helicobacter pylori activates Toll-like receptor 4 expression in gastrointestinal epithelial cells Infect Immun 71 2003 3496-3502.
58. Smith MF., Mitchell A Jr., Li G., et al. TLR2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells J Biol Chem 278 2003 32552-32560.
59. Mandell L., Moran AP., Cocchiarella A., et al. Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4 Infect Immun 72 2004 6446-6454.
60. Gewirtz AT., Yu Y., Krishna US., et al. Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity J Infect Dis 189 2004 1914-1920.
61. Naumann M., Crabtree JE Helicobacter pylori-induced epithelial cell signalling in gastric carcinogenesis Trends Microbiol 12 2004 29-36.
62. Elliott SN., Ernst PB., Kelly CP The year in Helicobacter pylori 2001: Molecular inflammation Curr Opin Gastroenterol 17 2002 s12-s18.
63. Israel DA., Salama N., Arnold CN., et al. Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses J Clin Invest 107 2001 611-620.
64. Ogura K., Maeda S., Nakao M., et al. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbil J Exp Med 192 2000 1601-1610.
65. Day AS., Jones NL., Lynett JT., et al. cagE is a virulence factor associated with Helicobacter pylori-induced duodenal ulceration in children J Infect Dis 181 2000 1370-1375.
66. Yahiro K., Wada A., Nakayama M., et al. Protein-tyrosine phosphatase alpha, RPTP alpha, is a Helicobacter pylori VacA receptor J Biol Chem 278 2003 19183-19189.
67. Cover TL The vacuolating cytotoxin of Helicobacter pylori Mol Microbiol 20 1996 241-246.
68. van Doorn LJ., Figueiredo C., Megraud F., et al. Geographic distribution of vacA allelic types of Helicobacter pylori Gastroenterology 116 1999 823-830.
69. Fujikawa A., Shirasaka D., Yamamoto S., et al. Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori Nat Genet 33 2003 375-381.
70. Atherton JC., Cao P., Peek RM., et al. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration J Biol Chem 270 1995 17771-17777.
71. Cover TL., Krishna US., Israel DA., Peek RM Induction of gastric epithelial cell apoptosis by Helicobacter pylori vacuolating cytotoxin Cancer Res 63 2003 951-957.
72. Macarthur M., Hold GL., El-Omar EM Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy Am J Physiol Gastrointest Liver Physiol 286 2004 G515-G520.
73. El-Omar E., Carrington M., Chow WH., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer Nature 404 2000 398-402.
74. Furuta T., El-Omar EM., Xiao F., et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan Gastroenterology 123 2002 92-105.
75. El-Omar EM., Rabkin CS., Gammon MD., et al. Chow. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms Gastroenterology 124 2003 1193-1201.
76. Machado JC., Figueiredo C., Canedo P., et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma Gastroenterology 125 2003 364-371.
77. Segal ED., Cha J., Lo J., et al. Altered states: Involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori Proc Natl Acad Sci U S A 96 1999 14559-14564.
78. Amieva MR., Vogelmann R., Covacci A., et al. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA Science 300 2003 1430-1434.
79. Maeda S., Yoshida H., Ogura K., et al. H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells Gastroenterology 119 2000 97-108.
80. Keates S., Keates AC., Warny M., et al. Differential activation of mitogen-activated protein kinases in AGS gastric epithelial cells by cag+ and cag-Helicobacter pylori J Immunol 163 1999 5552-5559.
81. Naumann M., Wessler S., Bartsch C., et al. Activation of activator protein 1 and stress response kinases in epithelial cells colonized by Helicobacter pylori encoding the cag pathogenicity island J Biol Chem 274 1999 31655-31662.
82. Takahashi S., Keto Y., Fujita T., et al. FR167653, a p38 mitogen-activated protein kinase inhibitor, prevents Helicobacter pylori-induced gastritis in Mongolian gerbils J Pharmacol Exp Ther 296 2001 48-56.
83. 2 increases AP endonuclease-1/redox factor-1 expression in human gastric epithelial cells Gastroenterology 127 2004 845-858.
84. O’Hara AM., Bhattacharyya A., Mifflin RC., et al. Interleukin-8 induction by Helicobacter pylori in human gastric epithelial cells is dependent on apurinic/apyrimidinic endonuclease-2/redox factor-1 J Immuol 177 2006 7990-7999.
85. Serafini M., Bellocco R., Wolk A., Ekstrom AM Total antioxidant potential of fruit and vegetables and risk of gastric cancer Gastroenterology 123 2002 985-991.
86. Fahey JW., Haristoy X., Dolan PM., et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors Proc Natl Acad Sci U S A 99 2002 7610-7615.
87. Stein M., Rappuoli R., Covacci A Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation Proc Natl Acad Sci U S A 97 2000 1263-1268.
88. Higashi H., Tsutsumi R., Muto S., et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein Science 295 2002 683-686.
89. Selbach M., Moese S., Hauck CR., et al. Src is the kinase of the Helicobacter pylori CagA protein in vitro and in vivo J Biol Chem 277 2002 6775-6778.
90. Tanaka J., Suzuki T., Mimuro H., Sasakawa C Structural definition on the surface of Helicobacter pylori type IV secretion apparatus Cell Microbiol 5 2003 395-404.
91. Tsutsumi R., Higashi H., Higuchi M., et al. Attenuation of Helicobacter pylori CagA x SHP-2 signaling by interaction between CagA and C-terminal Src kinase J Biol Chem 278 2003 3664-3670.
92. Higashi H., Tsutsumi R., Fujita A., et al. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites Proc Natl Acad Sci U S A 99 2002 14428-14433.
93. Higashi H., Nakaya A., Tsutsumi R., et al. Helicobacter pylori CagA induces Ras-independent morphogenetic response through SHP-2 recruitment and activation J Biol Chem 279 2004 17205-17216.
94. Hirata Y., Maeda S., Mitsuno Y., et al. Helicobacter pylori CagA protein activates serum response element-driven transcription independently of tyrosine phosphorylation Gastroenterology 123 2002 1962-1971.
95. El Etr SH., Mueller A., Tompkins LS., et al. Phosphorylation-independent effects of CagA during interaction between Helicobacter pylori and T84 polarized monolayers J Infect Dis 190 2004 1516-1523.
96. Yamaoka Y., Kwon DH., Graham DY A M(r) 34, 000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori Proc Natl Acad Sci U S A 97 2000 7533-7538.
97. Yamaoka Y., Kikuchi S., El Zimaity HM., et al. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production Gastroenterology 123 2002 414-424.
98. Viala J., Chaput C., Boneca IG., et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island Nat Immunol 5 2004 1166-1174.
99. Satin B., Del Giudice G., Della B., et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor J Exp Med 191 2000 1467-1476.
100. Rieder G., Einsiedl W., Hatz RA., et al. Comparison of CXC chemokines ENA-78 and interleukin-8 expression in Helicobacter pylori-associated gastritis Infect Immun 69 2001 81-88.
101. Eck M., Schmausser B., Scheller K., et al. CXC chemokines Gro(alpha)/IL-8 and IP-10/MIG in Helicobacter pylori gastritis Clin Exp Immunol 122 2000 192-199.
102. Harris PR., Mobley HLT., Perez-Perez GI., et al. Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production Gastroenterology 111 1996 419-425.
103. Gobert AP., Bambou JC., Werts C., et al. Helicobacter pylori heat shock protein 60 mediates interleukin-6 production by macrophages via a toll-like receptor (TLR)-2-, TLR-4-, and myeloid differentiation factor 88-independent mechanism J Biol Chem 279 2004 245-250.
104. Shimoyama T., Everett SM., Dixon MF., et al. Chemokine mRNA expression in gastric mucosa is associated with Helicobacter pylori cagA positivity and severity of gastritis J Clin Pathol 51 1998 765-770.
105. Haeberle HA., Kubin M., Bamford KB., et al. Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed Helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in the human gastric mucosa Infect Immun 65 1997 4229-4235.
106. Hafsi N., Voland P., Schwendy S., et al. Human dendritic cells respond to Helicobacter pylori, promoting NK cell and Th1-effector responses in vitro J Immunol 173 2004 1249-1257.
107. Tomita T., Jackson AM., Hida N., et al. Expression of interleukin-18, a Th1 cytokine, in human gastric mucosa is increased in Helicobacter pylori infection J Infect Dis 183 2001 620-627.
108. Ceponis PJ., McKay DM., Menaker RJ., et al. Helicobacter pylori infection interferes with epithelial Stat6-mediated interleukin-4 signal transduction independent of cagA, cagE, or VacA J Immunol 171 2003 2035-2041.
109. Luzza F., Parrello T., Monteleone G., et al. Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa J Immunol 165 2000 5332-5337.
110. Sebkova L., Pellicano A., Monteleone G., et al. Extracellular signal-regulated protein kinase mediates interleukin 17 (IL-17)-induced IL-8 secretion in Helicobacter pylori-infected human gastric epithelial cells Infect Immun 72 2004 5019-5026.
111. Lehmann FS., Terracciano L., Carena I., et al. In situ correlation of cytokine secretion and apoptosis in Helicobacter pylori-associated gastritis Am J Physiol Gastrointest Liver Physiol 283 2002 G481-G488.
112. Zavros Y., Rathinavelu S., Kao JY., et al. Treatment of Helicobacter gastritis with interleukin-4 requires somatostatin Proc Natl Acad Sci 100 2003 12944-12949.
113. Wang J., Fan XJ., Lindholm C., et al. Helicobacter pylori modulates lymphoepithelial cell interactions leading to epithelial cell damage through Fas/Fas Ligand interactions Infect. Immun 68 2000 4303-4311.
114. Rudi J., Kuck D., Strand S., et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis J Clin Invest 102 1998 1506-1514.
115. D’Elios MM., Bergman MP., Azzurri A., et al. H(+), K(+)-atpase (proton pump) is the target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis Gastroenterology 120 2001 377-386.
116. Fox JG., Beck P., Dangler CA., et al. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces Helicobacter-induced gastric atrophy Nat Med 6 2000 536-542.
117. Sakaguchi S., Fukuma K., Kuribayashi K., Masuda T Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease J Exp Med 161 1985 72-87.
118. Okazaki K., Ohana M., Oshima C., et al. Interaction of Helicobacter pylori-induced follicular gastritis and autoimmune gastritis in BALB/c mice with post-thymectomy autoimmune gastritis J Gastroenterol 38 2003 1131-1137.
119. Lundgren A., Suri-Payer E., Enarsson K., et al. Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals Infect Immun 71 2003 1755-1762.
120. Negrini R., Lisato L., Zanella I., et al. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa Gastroenterology 101 1991 437-445.
121. Appelmelk BJ., Simoons-Smit I., Negrini R., et al. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity Infect Immun 64 1996 2031-2040.
122. Yokota K., Kobayashi K., Kawahara Y., et al. Gastric ulcers in SCID mice induced by Helicobacter pylori infection after transplanting lymphocytes from patients with gastric lymphoma Gastroenterology 117 1999 893-899.
123. Gobert AP., McGee DJ., Akhtar M., et al. Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival Proc Natl Acad Sci U S A 98 2001 13844-13849.
124. Byrd JC., Yunker CK., Xu QS., et al. Inhibition of gastric mucin synthesis by Helicobacter pylori Gastroenterology 118 2000 1072-1079.
125. Allen LA., Schlesinger LS., Kang B Virulent strains of Helicobacter pylori demonstrate delayed phagocytosis and stimulate homotypic phagosome fusion in macrophages J Exp Med 191 2000 115-128.
126. Molinari M., Salio M., Galli C., et al. Selective inhibition of Ii-dependent antigen presentation by Helicobacter pylori toxin VacA J Exp Med 187 1998 135-140.
127. Koyama S Apoptotic depletion of infiltrating mucosal lymphocytes associated with Fas ligand expression by Helicobacter pylori-infected gastric mucosal epithelium: human glandular stomach as a site of immune privilege Dig Dis Sci 45 2000 773-780.
128. Betten A., Bylund J., Cristophe T., et al. A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis J Clin Invest 108 2001 1221-1228.
129. Wang J., Brooks EG., Bamford KB., et al. Negative selection of T cells by Helicobacter pylori as a model for bacterial strain selection by immune evasion J Immunol 167 2001 926-934.
130. Gebert B., Fischer W., Weiss E., et al. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation Science 301 2003 1099-1102.
131. Boncristiano M., Paccani SR., Barone S., et al. The Helicobacter pylori vacuolating toxin inhibits T cell activation by two independent mechanisms J Exp Med 198 2003 1887-1897.
132. Sundrud MS., Torres VJ., Unutmaz D., Cover TL Inhibition of primary human T cell proliferation by Helicobacter pylori vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion Proc Natl Acad Sci U S A 101 2004 7727-7732.
133. Zabaleta J., McGee DJ., Zea AH., et al. Helicobacter pylori arginase inhibits T cell proliferation and reduces the expression of the TCR zeta-chain (CD3zeta) J Immunol 173 2004 586-593.
134. Correa P., Houghton J Carcinogenesis of Helicobacter pylori Gastroenterology 133 2007 659-672.
135. Fennerty MB Gastric intestinal metaplasia on routine endoscopic biopsy Gastroenterology 125 2003 586-590.
136. Malfertheiner P., Peitz U The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia Gut 54 Suppl 1 2005 i13-i20.
137. McColl KE Helicobacter pylori and oesophageal cancer-Not always protective Gut 56 2007 457-459.
138. Huang JQ., Zheng GF., Sumanac K., et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer Gastroenterology 125 2003 1636-1644.
139. Goodman KJ., Joyce SL., Ismond KP Extragastric diseases associated with Helicobacter pylori infection Curr Gastroenterol Rep 8 2006 458-464.
140. Franchini M., Veneri D Helicobacter pylori-associated immune thrombocytopenia Platelets 17 2006 71-77.
141. Asahi A., Nishimoto T., Okazaki Y., et al. Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenia purpura patients J Clin Invest 118 2008 2939-2949.
142. DuBois S., Kearney DJ Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence Am J Gastroenterol 100 2005 453-459.
143. NIH Consensus ConferenceHelicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease JAMA 272 1994 65-69.
144. Malfertheiner P., Megraud F., O’Morain C., et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report Gut 56 2007 772-781.
145. Fujioka T., Yoshiiwa A., Okimoto T., et al. Guidelines for the management of Helicobacter pylori infection in Japan: Current status and future prospects J Gastroenterol 17 2007 3-6.
146. Chey WD., Wong BC American College of Gastroenterology guideline on the management of Helicobacter pylori infection Am J Gastroenterol 102 2007 1808-1825.
147. Talley NJ., Vakil N Guidelines for the management of dyspepsia Am J Gastroenterol 100 2005 2324-2337.
148. Moayyedi P., Deeks J., Talley NJ., et al. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: Resolving the discrepancy between systematic reviews Am J Gastroenterol 98 2003 2621-2626.
149. Chey WD., Moayyedi P Review article: Uninvestigated dyspepsia and non-ulcer dyspepsia-the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy Aliment Pharmacol Ther 1 2004 1-8.
150. Malfertheiner P., Sipponen P., Naumann M., et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: A state-of-the-art critique Am J Gastroenterol 100 2005 2100-2115.
151. Rostami N., Keshtkar-Jahromi M., Rahnavardi M., et al. Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: A controlled trial Am J Hematol 83 2008 376-381.
152. Versalovic J Helicobacter pylori. Pathology and diagnostic strategies Am J Clin Pathol 119 2003 403-412.
153. Megraud F., Lehours P Helicobacter pylori detection and antimicrobial susceptibility testing Clin Microbiol Rev 20 2007 280-322.
154. Midolo P., Marshall BJ Accurate diagnosis of Helicobacter pylori. Urease tests Gastroenterol Clin North Am 29 2000 871-878.
155. Gisbert JP., Abraira V Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: A systematic review and meta-analysis Am J Gastroenterol 101 2006 848-863.
156. Gatta L., Vakil N., Ricci C., et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection Am J Gastroenterol 99 2004 823-829.
157. el-Zimaity HM Accurate diagnosis of Helicobacter pylori with biopsy Gastroenterol Clin North Am 29 2000 863-869.
158. Wright CL., Kelly JK The use of routine special stains for upper gastrointestinal biopsies Am J Surg Pathol 30 2006 357-361.
159. Gerrits MM., van Vliet AH., Kuipers EJ., Kusters JG Helicobacter pylori and antimicrobial resistance: Molecular mechanisms and clinical implications Lancet Infect Dis 6 2006 699-709.
160. Marchildon P., Balaban DH., Sue M., et al. Usefulness of serological IgG antibody determinations for confirming eradication of Helicobacter pylori infection Am J Gastroenterol 94 1999 2105-2108.
161. Quesada M., Calvet X., Dosal A., et al. Evaluation of four different fecal tests for determination of cure after Helicobacter pylori treatment J Clin Gastroenterol 40 2006 790-794.
162. Chisholm SA., Owen RJ Application of polymerase chain reaction-based assays for rapid identification and antibiotic resistance screening of Helicobacter pylori in gastric biopsies Diagn Microbiol Infect Dis 61 2008 67-71.
163. Vakil N., Megraud F Eradication therapy for Helicobacter pylori Gastroenterology 133 2007 985-1001.
164. Megraud F Hpylori antibiotic resistance: Prevalence, importance, and advances in testing Gut 53 2004 1374-1384.
165. Peura DATreatment of Helicobacter pylori infection In: Wolfe MM Therapy of digestive disorders 2006 Elsevier Philadelphia 277.
166. Jodlowski TZ., Lam S., Ashby CR Emerging therapies for the treatment of Helicobacter pylori infections Ann Pharmacother 42 2008 1621-1639.
167. Gisbert JP., Castro-Fernandez M., Bermejo F., et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures Am J Gastroenterol 101 2006 243-247.
168. Gisbert JP., Gonzalez L., Calvet X., et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: A meta-analysis of eradication of helicobacter pylori [In process citation] Aliment Pharmacol Ther 14 2000 1319-1328.
169. Vaira D., Zullo A., Vakil N., et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A randomized trial Ann Intern Med 146 2007 556-563.
170. Jafri NS., Hornung CA., Howden CW Meta-analysis: Sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment Ann Intern Med 148 2008 923-931.
171. Laine L., Hunt R., El-Zimaity H., et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: A prospective, randomized, multicenter, North American trial Am J Gastroenterol 98 2003 562-567.
172. Lara LF., Cisneros G., Gurney M., et al. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection Arch Intern Med 163 2003 2079-2084.
173. Broutet N., Tchamgoue S., Pereira E., et al. Risk factors for failure of Helicobacter pylori therapy-Results of an individual data analysis of 2751 patients Aliment Pharmacol Ther 17 2003 99-109.
174. Suzuki T., Matsuo K., Ito H., et al. Smoking increases the treatment failure for Helicobacter pylori eradication Am J Med 119 2006 217-224.
175. Kearney DJ Retreatment of Helicobacter pylori infection after initial treatment failure Am J Gastroenterol 96 2001 1335-1339.
176. Osato MS., Reddy R., Reddy SG., et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States Arch Intern Med 161 2001 1217-1220.
177. Meyer JM., Silliman NP., Wang W., et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999 Ann Intern Med 136 2002 13-24.